Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
← catalyst calendarNCT07607587 · readout in 457 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
114estimated
Sites
11
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-29 | actual | When the study began enrolling |
| Primary completion | 2027-11-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-19 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obesity
- Overweight
Interventions
- Drug: Cagrilintide
- Drug: Placebo (matched to Cagrilintide)
Primary outcome
what the primary-completion date above is the date OFPercentage of participants on standard dose or higher dose (yes/no) of cagrilintide and placebo
measured At week 26
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed